Genocea Biosciences in the spotlight (part II)

Boutique data analysis of results presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Genocea (GNCA) reported underwhelming data at AACR for their targeted TIL approach, GEN-011. Genocea was using neoantigen reactive T-cells drawn from the peripheral blood of a cancer patient and identified only the neoantigen specific T-cells from the blood sample. These specific T-cells were selected, expanded, and re-injected back into the patient. Mo…